Black Hawk Acquisition Corporation Class A Ordinary Shares
BKHA
Black Hawk Acquisition Corp is a Blank check company.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$6.09 – $8.07
Volume35,219
Market cap$30M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for BKHA.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for BKHA.
Recent news
Company coverage with links to the original publishers.
Vesicor Therapeutics, a biotech company developing p53-based cancer therapeutics, announced the appointment of Michael Tolentino, M.D. as Chief Executive Officer effective March 17, 2026. Tolentino, a serial entrepreneur with over 20 years of biotech experience, succeeds founder Luo Feng who transitions to Chief Scientific Officer. The leadership change comes as Vesicor prepares to complete its proposed de-SPAC merger with Black Hawk Acquisition Corporation and accelerate IND-enabling studies with an FDA submission targeted for 2027.
Vesicor Therapeutics, a biotechnology company focused on p53-based cancer therapeutics, has entered into a business combination agreement with Black Hawk Acquisition Corporation to create a public company advancing its drug candidate.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.